Document Detail


Comparison of rates of reported adverse events associated with i.v. iron products in the United States.
MedLine Citation:
PMID:  22302256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: An analysis of reported adverse events (AEs) among patients using i.v. iron products, including the newer agent ferumoxytol, is presented.
METHODS: All AE reports to the Food and Drug Administration (FDA) citing iron sucrose, ferric gluconate, high- and low-molecular-weight iron dextran products, or ferumoxytol from October 2009 through June 2010 were evaluated. The rates of various classifications of reported AEs were calculated on a per-unit-sold basis and, for comparison of products supplied in different unit sizes, also in terms of 100-mg dose equivalents (DEq) of iron.
RESULTS: A total of 197 reported AEs were identified (a cumulative rate of 14.1 AEs per million units sold). The rates of all AE classifications combined ranged from 5.25 to 746 per million units sold for iron sucrose and ferumoxytol, respectively; using the other method of calculation, the rates ranged from 5.24 per million DEq (iron sucrose) to 147 per million DEq (ferumoxytol). Relative to iron sucrose and sodium ferric gluconate, ferumoxytol was associated with significantly elevated risks of death (odds ratio [OR], 475 and 156, respectively; p < 0.0001), serious nonfatal AEs (OR, 263 and 121, respectively; p < 0.0001), and all evaluated AE classifications combined (OR, 142 and 109, respectively; p < 0.05).
CONCLUSION: Analysis of reports submitted to FDA revealed large differences among i.v. iron products in reported deaths, serious AEs, other major AEs, and other AEs. Iron sucrose and sodium ferric gluconate were associated with much lower rates of AEs per million units sold than iron dextran or ferumoxytol, which were associated with the highest rates of all reported AE classifications.
Authors:
George R Bailie
Related Documents :
77416 - Elevated metabolic rates in obesity.
17021366 - Homeostatic and non-homeostatic pathways involved in the control of food intake and ene...
17122076 - Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and in...
19931066 - Nutritional deficiencies in obesity and after bariatric surgery.
17698276 - A critical review of the data related to the safety of quercetin and lack of evidence o...
19878276 - Peripheral oscillators: the driving force for food-anticipatory activity.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  69     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-03     Completed Date:  2012-05-21     Revised Date:  2012-07-05    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  310-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adverse Drug Reaction Reporting Systems / statistics & numerical data*
Commerce / statistics & numerical data*
Databases, Factual / statistics & numerical data
Ferric Compounds / administration & dosage,  adverse effects*,  economics
Humans
Injections, Intravenous
Odds Ratio
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Ferric Compounds
Comments/Corrections
Comment In:
Am J Health Syst Pharm. 2012 Jun 1;69(11):922-3   [PMID:  22610021 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy.
Next Document:  Monitoring adverse drug reactions across a nationwide health care system using information technolog...